These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22164689)

  • 41. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
    Okada K; Koike K; Sawa Y
    Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmaceutical product quality control and good manufacturing practices].
    Hiyama Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A century of health protection.
    Summers JL
    Can J Hosp Pharm; 1975; 28(5):143. PubMed ID: 10297116
    [No Abstract]   [Full Text] [Related]  

  • 44. [Chapter 3. Transitions in clinical trials and appropriate use of drugs in Japan (1980-2010)].
    Koshimizu T
    Yakushigaku Zasshi; 2014; 49(1):50-63. PubMed ID: 25272637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan.
    Nishiyama K; Toyoshima S; Yamada H; Suzuki H; Nagai N
    Ther Innov Regul Sci; 2018 Nov; 52(6):731-738. PubMed ID: 29714577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
    Asano K; Tanaka A; Sato T; Uyama Y
    Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Social issues in the history of nursing after World War II: establishment of Ministry of Welfare, Nursing Training and Research Center for nurse educators].
    Shimizu K
    Kango; 1985 Mar; 37(3):40-50. PubMed ID: 3906219
    [No Abstract]   [Full Text] [Related]  

  • 48. [The history of drug reevaluation in Japan].
    Takahashi H
    Yakushigaku Zasshi; 2010; 45(2):93-100. PubMed ID: 21661234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Regulation for Bioequivalence Evaluations of Generic Ophthalmic Dosage Forms in Japan.
    Myoenzono A; Kuribayashi R; Yamaguchi T; Ogawa T; Takagi K
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):697-702. PubMed ID: 32930951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medical device legislation.
    Miller MJ
    Hospitals; 1973 Jun; 47(11):81-8. PubMed ID: 4706560
    [No Abstract]   [Full Text] [Related]  

  • 51. Clarifying the Discussion Points in New Drug Application Reviews for Approval in Japan by a Government Advisory Council.
    Hattori Y; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2017 Jul; 51(4):426-430. PubMed ID: 30227059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Activity report on a programe of the Ministry of Health, Labour and Welfare (MHLW) "Initiative to facilitate development of innovative drugs, medical devices, and cellular and tissue-based products" in National Institute of Health Sciences].
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):1-2. PubMed ID: 25707193
    [No Abstract]   [Full Text] [Related]  

  • 53. [Reform of Japan's NTP and its technical perspectives].
    Mori T
    Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Drug control in Belgium: a brief history of drug laws (drugs for human use)].
    Oslet J
    J Pharm Belg; 2007; 62(4):123-9. PubMed ID: 18269140
    [No Abstract]   [Full Text] [Related]  

  • 55. Patient access to medical devices-what about Japan, the second largest medical device market?
    Ikeno F; Ikeda K; Uchida T
    Cardiovasc Interv Ther; 2014 Jan; 29(1):1-3. PubMed ID: 23975639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
    Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
    Tanaka M; Nagata T
    Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PMDA's challenge to accelerate clinical development and review of new drugs in Japan.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Oct; 88(4):454-7. PubMed ID: 20856242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Action of medical facilities on the revised pharmaceutical affairs law -part 1-].
    Hayakawa T
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2004 Nov; 60(11):1516-7. PubMed ID: 15568002
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.